1. Christensen DM, Schjerning AM, Smedegaard L, et al. Long-term mortality, cardiovascular events, and bleeding in stable patients 1 year after myocardial infarction: a Danish nationwide study. Eur Heart J 2023;44:488–498.

2. Lee JM, Choi KH, Song YB, et al.; RENOVATE-COMPLEX-PCI Investigators. Intravascular imaging-guided or angiography-guided complex PCI. N Engl J Med 2023;388:1668–1679.

3. Brener SJ, Tarantini G, Leon MB, et al. Cardiovascular and noncardiovascular death after percutaneous coronary intervention: insights from 32 882 patients enrolled in 21 randomized trials. Circ Cardiovasc Interv 2018;11:e006488.

4. Yamashita Y, Shiomi H, Morimoto T, et al.; CREDO-Kyoto AMI Registry Investigators. Cardiac and noncardiac causes of long-term mortality in ST-segment-elevation acute myocardial infarction patients who underwent primary percutaneous coronary intervention. Circ Cardiovasc Qual Outcomes 2017;10:e002790.

5. Ibanez B, James S, Agewall S, et al.; ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018;39:119–177.

6. Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2022;145:e18.

7. Fanaroff AC, Roe MT, Clare RM, et al. Competing risks of cardiovascular versus noncardiovascular death during long-term follow-up after acute coronary syndromes. J Am Heart Assoc 2017;6:e005840.

8. Lee SH, Hyun D, Choi J, et al. Adherence to guideline-directed medical therapy and 3-year clinical outcome following acute myocardial infarction. Eur Heart J Open 2023;3:oead029.

9. Austin PC, Putter H, Lee DS, Steyerberg EW. Estimation of the absolute risk of cardiovascular disease and other events: issues with the use of multiple Fine-Gray subdistribution hazard models. Circ Cardiovasc Qual Outcomes 2022;15:e008368.

10. Hageman SHJ, Dorresteijn JAN, Pennells L, et al. The relevance of competing risk adjustment in cardiovascular risk prediction models for clinical practice. Eur J Prev Cardiol 2023;30:1741–1747.

11. Denz R, Klaaßen-Mielke R, Timmesfeld N. A comparison of different methods to adjust survival curves for confounders. Stat Med 2023;42:1461–1479.

12. Dignam JJ, Zhang Q, Kocherginsky M. The use and interpretation of competing risks regression models. Clin Cancer Res 2012;18:2301–2308.

13. Gregson J, Sharples L, Stone GW, Burman CF, Öhrn F, Pocock S. Nonproportional hazards for time-to-event outcomes in clinical trials: JACC review topic of the week. J Am Coll Cardiol 2019;74:2102–2112.

14. Garcia RA, Spertus JA, Benton MC, et al.; ISCHEMIA Research Group. Association of medication adherence with health outcomes in the ISCHEMIA trial. J Am Coll Cardiol 2022;80:755–765.

15. Kochar A, Mulder H, Rockhold FW, et al. Cause of death among patients with peripheral artery disease: insights from the EUCLID trial. Circ Cardiovasc Qual Outcomes 2020;13:e006550.

16. Jankowski J, Floege J, Fliser D, Böhm M, Marx N. cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options. Circulation 2021;143:1157–1172.

17. Porter C, Azam TU, Mohananey D, et al. Permissive cardiotoxicity: the clinical crucible of cardio-oncology. JACC CardioOncol 2022;4:302–312.

18. Bricker RS, Valle JA, Plomondon ME, Armstrong EJ, Waldo SW. Causes of mortality after percutaneous coronary intervention. Circ Cardiovasc Qual Outcomes 2019;12:e005355.

19. Pedersen F, Butrymovich V, Kelbæk H, et al. Short- and long-term cause of death in patients treated with primary PCI for STEMI. J Am Coll Cardiol 2014;64:2101–2108.

20. Valgimigli M, Garcia-Garcia HM, Vrijens B, et al. Standardized classification and framework for reporting, interpreting, and analysing medication non-adherence in cardiovascular clinical trials: a consensus report from the Non-adherence Academic Research Consortium (NARC). Eur Heart J 2019;40:2070–2085.

21. Camacho X, Nedkoff L, Wright FL, et al. Relative contribution of trends in myocardial infarction event rates and case fatality to declines in mortality: an international comparative study of 1·95 million events in 80·4 million people in four countries. Lancet Public Health 2022;7:e229–e239.